Find clinical trials | Bayside Health (Alfred)

PROMPT

Ultra-hyPofractionated stereotactic Radiation therapy for de nOvo Metastatic ProsTate cancer (ACTRN12626000470392)

A prospective, multi-centre, single-arm non-randomised phase 2 clinical trial. This study will aim to deliver SABR to the prostate 35 Gy in 5 fractions, one fraction per week, in individuals with de novo metastatic prostate cancer.

Currently recruiting

PROMPT O2

Perioperative Medicine Platform Trial (NCT07186634)

Giving a lot of oxygen may decrease the risk of infections after surgery. On the other hand, it is also possible that giving a conservative amount of oxygen (instead of a large amount) might protect organ functions and improve other aspects of recovery after surgery. We are comparing three (3) different ways of giving oxygen. You have an equal chance of receiving one of the following three treatments during and after surgery: Liberal oxygen - at least 80% oxygen; Conservative oxygen - the smallest amount of oxygen needed to safely achieve normal oxygen levels in the blood (but more than the oxygen in room air); Standard oxygen - oxygen in a middle range between the liberal and conservative treatments.

Currently recruiting

PROSPERO

A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (NCT05742802)

Currently recruiting

PRT2527-02

A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 in Participants with Relapsed/Refractory Hematologic Malignancies (NCT05665530)

Currently recruiting

PSO-Withdraw

A Proof-of-concept Single-arm clinical trial Of semaglutide after withdrawal of biologic therapy for chronic plaque psoriasis in people with overweight/obesity [PSO-withdraw] (Trial Not Registered)

This study is seeking adults who are currently on a biologic therapy for their chronic plaque psoriasis and are classified as overweight/obese. The study aims to investigate whether starting semaglutides after stopping biologic therapy can maintain disease remission in this patient population. Eligible participants will be followed over one year and need to attend the Alfred Hospital for at least 10 visits over this time. Blood samples, quality of life questionnaires and assessments will be undertaken at each of these visits.

Currently recruiting

PT-22-001

A Phase Ib Dose Escalation/Dose Expansion Study of PTM-101 as an Adjunct to Neoadjuvant Therapy for Treatment Naïve, Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma [PDAC]. (NCT06673017)

This is a multi-centre, non-randomized, single-arm, open-label, phase Ib, dose escalation/dose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-naïve subjects with borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC).

Currently recruiting

PTeye

Assessing Benefits of Near Infrared Autofluorescence Detection for Identifying Parathyroid Glands during Endocrine Surgery (NCT05022667)

Currently recruiting

PTG-300-11

A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera (PTG-300-11) (NCT05210790)

No longer recruiting

PUMA

Pulmonary Artery Catheters in Adults Undergoing Cardiac Surgery [PUMA]: an International, Multicentre, Bayesian, Non-Inferiority Randomised Trial (NCT07612683)

To determine if perioperative management without a PAC is noninferior to perioperative management with a PAC with respect to days spent alive and at home by postoperative day 30 (DAH30) among adults undergoing low-risk cardiac surgery.

Currently recruiting

PWI in enduring PVI

Outcomes of redo atrial fibrillation ablation with posterior wall isolation in patients with enduring pulmonary vein isolation (Trial Not Registered)

To determine the effectiveness of posterior wall isolation in patients presenting for redo atrial fibrillation (AF) ablation with enduring pulmonary vein isolation (PVI).

Currently recruiting

QUANTUM-WILD

Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial Of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adult Patients With Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia

About the QuANTUM-Wild Study: QuANTUM-Wild is a clinical trial for people who are newly diagnosed with acute myeloid leukaemia (AML) that is FLT3-ITD–negative. The purpose of the clinical trial is to evaluate an oral study drug called quizartinib—to see if it may improve this type of AML and is safe. This study drug is currently not approved for this condition, which is why it’s being evaluated. Everyone in the clinical trial will also receive the standard chemotherapy for their type of AML. This clinical trial will not delay the start of chemotherapy. Your study doctor may recommend that you receive a stem cell transplant. If so, your study doctor will be able to provide you with more information about this procedure. Although it is not part of this clinical trial, you may be able to continue participating in the clinical trial after you receive a stem cell transplant.

Currently recruiting

QUINTESSENTIAL 1

A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel [BMS-986393], a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma [QUINTESSENTIAL] (NCT06297226)

The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.

Currently recruiting

R3767-ONC-2011

A Phase 3 Trial of Fianlimab (REGN3767, anti-Lag-3) + Cemiplimab versus Pembrolizumab in Patients with Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma (NCT05352672)

No longer recruiting

R3767-ONC-2055

A Phase 3 Trial of Fianlimab (anti-LAG-3) and Cemiplimab versus Pembrolizumab in the Adjuvant Setting in Patients with Completely Resected High-risk Melanoma (NCT05608291)

No longer recruiting

R3ACT-R

A randomised trial of most closely HLA-matched third-party donor-derived virus-specific cytotoxic T-lymphocytes in patients with untreated viral infection post-allogeneic stem cell transplantation (R3ACT Randomised (R3R)) (ACTRN12620000171910p)

Currently recruiting

R5458-ONC-2246

A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma [LINKER-MM5] (NCT07222761)

A study to compare linvoseltamab monotherapy and linvoseltamab + carfilzomib combination therapy with standard-of-care combination regimens in participants with relapsed/refractory multiple myeloma (RRMM).

Currently recruiting

Rainbow Trial [RAY902CT]

PHASE IB OPEN LABEL BASKET TRIAL OF RAY121 TO INHIBIT CLASSICAL COMPLEMENT PATHWAY IN IMMUNOLOGICAL DISEASES [RAINBOW TRIAL] (NCT06371417)

The RAY902CT study is designed to evaluate the safety and efficacy of RAY121 in adult participants with Bullous Pemphigoid (BP) or Behcet’s syndrome. Participants receive trial medication via a monthly injection under the skin (subcutaneous). The treatment period will be approximately 12 weeks with the option of a long-term extension.

Currently recruiting

RAPID STUDY

A multi-centre, pRospective, safety and efficacy evaluation study on Automated external defibrillation in PatIents with CellAED (ACTRN12621000258853)

No longer recruiting

RAPiD-I Study

First In Human Feasibility Clinical Study Evaluating the Safety of the XPD System for Periosteal Distraction [PD] (ACTRN12625000159459)

Chronic, non-healing foot and leg ulcers are often a result of reduced blood flow due to Peripheral Artery Disease (PAD) or other ischemic (reduced blood flow) conditions in patients with chronic diseases, such as diabetes. These ulcers can compromise quality of life and increase the risk of serious infection and result in injury and death of the tissue. The XPD is a new device that is designed to stretch the soft tissue around the bone (called the periosteum) to trigger the body’s natural healing process. It moves in a slow, controlled way to support healing and new tissue growth.

Currently recruiting

RASolve 301

RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 versus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC (NCT06881784)

Global, open-label, Phase 3 study, patients with locally advanced or metastatic RAS-mutant NSCLC will be randomized to RMC-6236 or docetaxel (in a 1:1 ratio) on a 21-day treatment cycle.

Currently recruiting